Anti-C1T9B/ C1QTNF9B/ CTRP9B functional antibody

Anti-C1T9B/ C1QTNF9B/ CTRP9B functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to C1QTNF9B/C1QTNF9B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE0718-Ab-1/ GM-Tg-hg-SE0718-Ab-2Anti-Human C1QTNF9B monoclonal antibodyHuman
GM-Tg-rg-SE0718-Ab-1/ GM-Tg-rg-SE0718-Ab-2Anti-Rat C1QTNF9B monoclonal antibodyRat
GM-Tg-mg-SE0718-Ab-1/ GM-Tg-mg-SE0718-Ab-2Anti-Mouse C1QTNF9B monoclonal antibodyMouse
GM-Tg-cynog-SE0718-Ab-1/ GM-Tg-cynog-SE0718-Ab-2Anti-Cynomolgus/ Rhesus macaque C1QTNF9B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE0718-Ab-1/ GM-Tg-felg-SE0718-Ab-2Anti-Feline C1QTNF9B monoclonal antibodyFeline
GM-Tg-cang-SE0718-Ab-1/ GM-Tg-cang-SE0718-Ab-2Anti-Canine C1QTNF9B monoclonal antibodyCanine
GM-Tg-bovg-SE0718-Ab-1/ GM-Tg-bovg-SE0718-Ab-2Anti-Bovine C1QTNF9B monoclonal antibodyBovine
GM-Tg-equg-SE0718-Ab-1/ GM-Tg-equg-SE0718-Ab-2Anti-Equine C1QTNF9B monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE0718-Ab-1/ GM-Tg-hg-SE0718-Ab-2; GM-Tg-rg-SE0718-Ab-1/ GM-Tg-rg-SE0718-Ab-2;
GM-Tg-mg-SE0718-Ab-1/ GM-Tg-mg-SE0718-Ab-2; GM-Tg-cynog-SE0718-Ab-1/ GM-Tg-cynog-SE0718-Ab-2;
GM-Tg-felg-SE0718-Ab-1/ GM-Tg-felg-SE0718-Ab-2; GM-Tg-cang-SE0718-Ab-1/ GM-Tg-cang-SE0718-Ab-2;
GM-Tg-bovg-SE0718-Ab-1/ GM-Tg-bovg-SE0718-Ab-2; GM-Tg-equg-SE0718-Ab-1/ GM-Tg-equg-SE0718-Ab-2
Products NameAnti-C1QTNF9B monoclonal antibody
Formatmab
Target NameC1QTNF9B
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-C1QTNF9B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE0718-Ag-1Recombinant multi-species C1T9B/ C1QTNF9B/ CTRP9B protein


    Target information

    Target IDGM-SE0718
    Target NameC1QTNF9B
    Gene ID387911
    Gene Symbol and SynonymsC1QTNF9B,CTRP9B
    Uniprot AccessionB2RNN3
    Uniprot Entry NameC1T9B_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000205863
    Target ClassificationN/A

    The target: C1QTNF9B, gene name: C1QTNF9B, also named as CTRP9B. Predicted to enable hormone activity and identical protein binding activity. Predicted to act upstream of or within several processes, including energy homeostasis; negative regulation of cell size; and positive regulation of protein serine/threonine kinase activity. Predicted to be located in extracellular space. Predicted to be part of collagen trimer. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.